Regio-controlled Michaelis–Arbuzov reactions of 3-(halomethyl)coumarins

Thompo J. Rashamuse, Musiliyu A. Musa, Rosalyn Klein and Perry T. Kaye*

Department of Chemistry and Centre for Chemico- and Biomedicinal Research, Rhodes University, Grahamstown, 6140, South Africa

3-(lodomethyl)coumarins and 3-(chloromethyl)coumarins, obtained chemoselectively *via* Baylis–Hillman reactions of salicylaldehyde derivatives with *t*-butyl acrylate, can be reacted with triethyl phosphite to afford regioisomeric Michaelis–Arbuzov products. Under nitrogen, the 3-(iodomethyl)coumarins undergo direct displacement of iodide to afford the expected 1'-phosphonated derivatives. The reactions with 3-(chloromethyl)coumarins in air, however, proceed with overall allylic rearrangement to afford the regioisomeric 3-methyl-4-phosphonated derivatives.

Keywords: 3-(chloromethyl)coumarins, 3-(iodomethyl)coumarins, Michaelis-Arbuzov reaction, allylic rearrangement

Many compounds containing the coumarin moiety (2*H*-1benzopyran-2-one), both naturally-occurring and synthetic, have been shown to exhibit interesting medicinal properties, including anti-inflammatory,^{1,2} antifungal³ and anti-HIV properties.⁴ Warfarin 1, for example, is used as an anticoagulant and has been shown to be weakly active against HIV-1 protease enzyme.⁵ Another 4-hydroxycoumarin derivative, phenprocoumon 2, acts as a competitive HIV-1 protease inhibitor and was identified as a lead structure in the design of non-peptidic inhibitors.⁶ The hydroxycoumarin, umbelliferone 3, is found in a variety of plants, and has been used as a sunscreen and as a fluorescence indicator.⁷⁻⁹



Numerous methods have been developed for the the synthesis of coumarins, including the Pechmann condensation,^{10,11} the Perkin reaction,¹¹ the Knoevenagel condensation¹² and the Wittig reaction.¹³ In our own group, particular attention has been given to applications of the Baylis–Hillman reaction in the construction of benzannulated heterocyclic systems,^{14,15} including coumarins.¹⁶⁻¹⁸ We have found that reaction of salicylaldehyde derivatives **4** with *t*-butyl acrylate using 1,4-diazabicyclo[2.2.2]octane (DABCO) as catalyst affords the *isolable* Baylis–Hillman adducts **5** (Scheme 1), which cyclise on treatment with HCl to form the 3-(chloromethyl)coumarin derivatives **6** in good yields (86–90%).¹⁸ This approach obviated the need to protect the nucleophilic phenolic group (*via* benzylation, as in 7) and thus prevent the formation of complex mixtures of chromene and coumarin deivatives (Scheme 1).^{16,17}

As part of an ongoing programme directed at the development of novel HIV-1 protease inhibitors,¹⁹ we have begun to explore the synthesis of various coumarin derivatives as potential inhibitors. In this paper, we discuss the formation of phosphonated coumarin derivatives *via* Arbuzov reactions of series of specially prepared 3-(chloromethyl)- and 3-(iodomethyl)coumarins.

Following our earlier procedure,¹⁸ the Baylis–Hillman adducts **5a–d** were reacted with hydrochloric acid in a mixture of acetic acid and acetic anhydride, under reflux for 2 hours, to give the 3-(chloromethyl)coumarin derivatives **6a–d** in yields of up to 94%. The Baylis–Hillman adducts **5a–d** were similarly reacted with hydriodic acid to give 3-(iodomethyl)coumarins **8a–d**, previously obtained



Scheme 1 Reagents and conditions: (i) PhCH₂Br, K₂CO₃, Nal, acetone; (ii) Methyl acrylate or *t*-butyl acrylate, DABCO, CHCl₃; (iii) HCl, Ac₂O, AcOH, reflux; (iv) HI, Ac₂O, AcOH, reflux.

using protection strategies.^{16,17} However, in the cases of the 5-chloro- and 5-bromo substrates (**5c,d**), the 3-methyl analogues **9c,d** were isolated together with the corresponding 3-(iodomethyl)coumarins **8c,d**. When the reaction mixtures containing the adducts **5c** and **5d** were refluxed for 8 hours, the 3-methyl analogues **9c,d** were obtained as the sole products – a result attributed to HI-mediated reduction of the initially formed 3-(iodomethyl)coumarins **8c,d**. In view of this complication, the reaction time for these two substrates (**9c,d**) was reduced to 1 h and the required 3-(iodomethyl)coumarins **8c** and **8d** were obtained as the sole products (see Table 1).

The 3-(halomethyl)coumarins (**6a–d** and **8a–d**) may be expected, in principle, to be susceptible to nucleophilic attack at one or more of three electrophilic centres (C-2, C-4 or C-1'; Fig. 1).

^{*} Correspondent. E-mail: P.Kaye@ru.ac.za







Fig. 1 Possible modes of nucleophilic attack on the 3-(halomethyl)coumarin derivatives 8 and 9.

The Michaelis-Arbuzov reaction, which involves heating alkyl halides with triethyl phosphite, provides convenient access to alkylphosphonate derivatives, the mechanism typically involving direct (S_N) displacement of halide.²⁰ However, when the 3-(chloromethyl)coumarin derivatives 6a-d were boiled under reflux with two equivalents of triethyl phosphite under solvent-free conditions in air (pathway I, Scheme 2), the 4phosphonated (S_N') products 12a-d were obtained in yields of up to 68% (Table 2), but none of the expected 1'-phosphonated products 11a-d. [Interestingly, reactions of 3-substituted coumarins with nitrogen and carbon nucleophiles, examined in an earlier study,²¹ appeared to proceed with exclusive, direct (S_N) substitution at the exocyclic C-1' electrophilic centre!] The 3-(chloromethyl)coumarin derivatives 6a-d were then treated with 2 equivalents of triethylphosphite under the same conditions, except that the reaction was conducted under nitrogen (pathway II;). Flash chromatography of the isolated material afforded both the 1'-phosphonated (S_N) products 11a-d (in yields of up to 67%) together with the 4-phosphonated (S_N') products 12a-d (in yields of up to 16%). Remarkably, when the 3-(iodomethyl)coumarins 8a-d were treated with 2 equivalents of triethyl phosphite under nitrogen, the 1'-phosphonated (S_N) products 11a-d were isolated with no trace of the 4-phosphorylated analogues 12a-d (pathway III, Scheme 2)! The role of nitrogen in these reactions, however, is not, as yet, understood.

Formation of the 1'-phosphonated products 11a-d presumably proceeds by direct (S_N) displacement of the halide anion (chloride or iodide), whereas displacement of chloride in formation of the 4-phosphonated analogues 12a-d could involve either an S_N' pathway or a conjugate addition-elimination sequence. The observed halide-specific regioselectivities may be tentatively rationalised in terms of the relative electronegativities of the halogen atoms and the leaving-group potential of the corresponding halide anions. Since iodide is a very good leaving group, the Michaelis–



Scheme 2 Reagents and conditions: (i) 2 equiv. P(OEt)₃, reflux, 4 h; (ii) 2 equiv. P(OEt)₃, N₂, reflux, 4 h.

Table 2Yields obtained for the synthesis of 1'-phosphorylatedproducts11a-dand4-phosphorylatedproducts12a-d(Scheme 2)



Substrate	х	R	Method ^a	Yield of 11/%	Yield of 12/%
6a	CI	Н	А	_	60
6b	CI	8-OEt	А	_	52
6c	CI	6-CI	А	_	68
6d	CI	6-Br	А	-	65
6a	CI	Н	В	43	16
6b	CI	8-OEt	В	67	14
6c	CI	6-CI	В	53	10
6d	CI	6-Br	В	53	8
8a	I	Н	В	61	_
8b	I	8-OEt	В	40	_
8c	I	6-CI	В	54	_
8d	I	6-Br	В	40	-

^aMethod A: Reflux in air. Method B: reflux under nitrogen.

Arbuzov reaction may well favour attack of phosphorus at the less hindered 1'-centre of an intermediate, delocalised allylic carbocation *via* a direct (S_N1) pathway. Chloride, on the other hand, is a somewhat poorer leaving group, and its bimolecular displacement by phosphorus could occur at *either* the sp³ allylic centre (C-1') *via* an S_N2 pathway *or*, preferentially, at the less-hindered sp² vinylic centre (C-4) *via* an S_N2' pathway, the electrophilicity of the latter centre being enhanced by the electron-withdrawing inductive effect of the more



Scheme 3 Mechanistic possibilities for the conjugate addition-elimination pathway.

electronegative chlorine. Alternatively, the mechanism for the formation of the 4-phosphonated analogues **12a–d** from the 3-(chloromethyl)coumarins derivatives **6a–d** could involve initial conjugate addition of $P(OEt)_3$ to the α,β -unsaturated carbonyl system to afford the intermediates **13a–d**. Concerted (Path I; Scheme 3) or step-wise (*via* intermediates **14**; Path II) routes, involving halide displacement and attack at one of the *O*-ethyl groups would both be expected to afford the common intermediates **15**. Rearrangement of the double bond would then afford the aromatic 4-phosphonated derivatives **12a–d**. Whatever the mechanism, the net result is, effectively, a Michaelis–Arbuzov reaction with allylic rearrangement – a process, which to our knowledge, is unprecedented!

All new products were fully characterised by elemental (HRMS) and spectroscopic (IR and 1- and 2-D NMR) analysis. In the ¹H NMR spectra of the 1'-phosphonate derivatives 11ad, the P-O-methylene protons typically resonate as a quartet at ca. 4.1 ppm, while the ¹³C NMR data are consistent with magnetic equivalence of both O-methylene carbons. The P-O-methylene protons in the 4-phosphonate derivatives 12a-d, on the other hand, resonate as a *pair* of discrete or overlapping multiplets in the region 4.1-4.3 ppm. The DEPT-135, HSQC and proton noise decoupled ¹³C NMR spectra of each of the 4-phosphonate derivatives 12a-d, however, indicate the presence of a single, P-O-methylene carbon doublet [e.g., for 12c: $\delta_C = 63.0$ (d, ${}^{3}J_{P,C} = 5.6$ Hz)] corresponding to the *pair* of methylene proton multiplets at ca 4.2 and 4.3 ppm. These observations are attributed to the diastereotopicity and, hence, magnetic non-equivalence of the geminal O-methylene protons on the magnetically equivalent O-methylene carbons.

Experimental

NMR spectra were recorded on Bruker AMX 400 and Biospin 600 spectrometers at 303K in DMSO- d_6 or CDCl₃ and calibrated using solvent signals [7.25 (CHCl₃) and 2.50 ppm (DMSO- d_6) for ¹H NMR; 77.0 (CDCl₃) and 34.5 (DMSO- d_6) for ¹³C NMR]. ³¹P NMR spectra were recorded using phosphoric acid (H₃PO₄) as an internal reference. Melting points were measured using a Kofler hot stage apparatus and are uncorrected. Flash column chromatography was performed using Merck Silica gel 60 [particle size 0.040–0.063 mm (230–400 mesh)] and MN Kieselgel 60 (particle size 0.063–0.200 mm). IR spectra were obtained on a Perkin Elmer FT-IR Spectrum 2000 spectrometer using nujol mulls. Low-resolution (EI) mass spectra were obtained on a Finnigan-Mat GCQ mass spectrometer and high-resolution (EI) mass spectra on a VG70-SEQ Micromass double-focusing magnetic sector spectrometer (Potchefstroom University Mass Spectrometry Unit). The reagents used in the present study were supplied by Aldrich and used without further purification.

Compounds **5a–d**, **6a–d**, **7** and **9c**,**d** are known.^{16,17} The 3-(iodomethyl)coumarins **8a–d** are also known,^{16,17} but their synthesis *via* the *tert*-butyl acrylate esters **5a–d** has not been published previously. The procedures used in this study are illustrated by the following examples.

3-(*iodomethyl*)*coumarin* (8a): Conc. HI (10 mL) was added to a solution of *tert*-butyl 3-hydroxy-3-(2-hydroxyphenyl)-2methylenepropanoate 5a (0.50 g, 2.0 mmol) in a mixture of AcOH (5 mL) and Ac₂O (5 mL). The mixture was boiled under reflux for 2 h, allowed to cool to room temperature and then poured into ice-cooled water (10 mL). Stirring for *ca* 30 min gave a precipitate, which was filtered off and washed with hexane to afford 3-(iodomethyl)coumarin 8a as a grey solid (0.35 g, 60%), m.p. 148–151 °C (lit.,¹⁶ 150–152 °C).

6-Chloro-3-(iodomethyl)coumarin **8c** and 6-chloro-3-methylcoumarin (**9c**): The procedure described for the synthesis of 3-(iodomethyl)coumarin **8a** was followed, using conc. HI (10 mL) and *tert*-butyl 3-(5-chloro-2-hydroxyphenyl)-3-hydroxy-2-methylenepropanoate **5c** (0.52 g, 2 mmol) in a mixture of AcOH (5 mL) and Ac₂O (5 mL). Work-up and chromatography [on silica gel; elution with ethyl acetate-chloroform-hexane (1:1:3)] afforded two fractions. *Fraction 1*: 6-Chloro-3-(iodomethyl)coumarin **8c** as a yellow solid (0.308 g, 52%), m.p. 186–189 °C (lit., ¹⁶ 188–190 °C). *Fraction 2*: 6-Chloro-3-methylcoumarin **9c** as pale yellow solid (0.162 g, 45%), m.p. 128–132 °C (lit., ²² 158–160 °C).

Michaelis-Arbuzov phosphonation: Method A

Diethyl (3-methyl-2-oxo-2H-chromen-4-yl)phosphonate (12a): To 3-(chloromethyl)coumarin **6a** (0.35 g, 1.3 mmol) was added triethyl phosphite (0.42 mL) and the mixture was boiled under reflux for 4 h. Upon completion of the reaction, as monitored by TLC, the mixture was separated by flash column chromatography [on silica gel; elution with ethyl acetate–hexane (3 : 1)] to afford *diethyl (3-methyl-2-oxo-2H-chromen-4-yl)phosphonate* **12a** as a yellow solid (0.318 g, 60%), m.p. 47–49 °C; (Found M⁺: 296.082484. C₁₄H₁₇O₅P requires M: 296.081362); v_{max} (nujol)/cm⁻¹ 1734 (C=O) and 1240 (P = O); $\delta_{\rm H}$ (400 MHz; CDCl₃) 1.34 (6H, t, *J* = 7 Hz, 2 × CH₂CH₃), 2.61 (3H, d, *J* = 3.2 Hz, 3-CH₃), 4.16 and 4.26 (4H, 2 × m, 2 × CH₂OP), 7.25-7.30 (2H, m, ArH), 7.46 (1H, m, ArH) and 8.49 (1H, dd, *J* = 8.2 and 1 Hz, ArH); $\delta_{\rm C}$ (100 MHz; CDCl₃) 16.26 (d, *J*_{PC} = 6.1 Hz, 2 × CH₂CH₃), 16.3 (3-CH₃), 62.8 (d, *J*_{PC} = 5.5 Hz, 2 × CH₂OP), 116.7 (d, *J*_{PC} = 2.6 Hz), 118.1 (d, *J*_{PC} = 11.2 Hz), 124.2, 128.0 (d, *J*_{PC} = 15. Hz), 130.6, 135.5 (d, *J*_{PC} = 23 Hz), 137.4 and 152.0 (d, *J*_{PC} = 13.2 Hz) (ArC), and 161.1 (d, *J*_{PC} = 13.2 Hz, C=O); *m/z* 296 (M⁺, 100%).

Michaelis-Arbuzov phosphonation: Method B

Diethyl [(2-oxo-2H-chromen-3-yl)methyl]phosphonate 11a and diethyl (3-methyl-2-oxo-2H-chromen-4-yl)phosphonate (12a): To 3-(chloromethyl)coumarin 6a (0.823 g, 4.3 mmol) was added triethyl phosphite (1.4 mL) and the mixture was refluxed under nitrogen for 4 h. Upon completion of the reaction, as monitored by TLC, the mixture was separated by flash column chromatography [on silica gel; elution with ethyl acetate-hexane (3:1)] to afford two fractions. *Fraction 1: Diethyl (3-methyl-2-oxo-2H-chromen-4-yl)phosphonate* (12a): Pale yellow solid (0.236 g, 16%).

Fraction 2: *Diethyl [(2-oxo-2*H-*chromen-3-yl)methyl]phosphonate* (**11a**): Pale brown oil (0.401 g, 43%); (Found M⁺: 296.079819. $C_{14}H_{17}O_5P$ requires *M*: 296.081362); v_{max} (nujol)/cm⁻¹ 1734 (C=O) and 1240 (P = O); δ_H (400 MHz; CDCl₃) 1.31 (6H, t, *J* = 7 Hz, 2×OCH₂CH₃), 3.18 (2H, d, *J*_{PH}=22Hz, CH₂P), 4.14 (4H, m, 2×CH₂OP), 7.25–7.52 (4H, series of multiplets, ArH) and 7.83 (1H, d, *J*_{PC} = 4.4 Hz, 4-H); δ_C (100 MHz; CDCl₃) 16.3 (d, *J*_{PC} = 6.1 Hz, 2×OCH₂CH₃), 26.7 (d, *J*_{PC}=139 Hz, CH₂P), 62.4 (d, *J*_{PC}=6.6 Hz, 2×CH₂OP), 116.4, 119.1 (d, *J*_{PC}=3.5 Hz), 120.5 (d, *J*_{PC}=7.9 Hz) and 153.2 (d, *J*_{PC}=1.8 Hz) (ArC) and 161.2 (d, *J*_{PC}=6.6 Hz, C=O); *m/z* 296 (M⁺, 90%) and 160 (100%).

Analytical data for other new compounds isolated in this study are as follows.

Diethyl [(8-ethoxy-2-oxo-2H-chromen-3-yl)methyl]phosphonate (11b): Yellow solid (0.83 g, 67%), m.p. 53–56 °C; (Found M⁺: 340.107526. C₁₆H₂₁O₆P requires *M*: 340.107577); v_{max} (nujol)/cm⁻¹ 1724 (C=O) and 1258 (P = O); $\delta_{\rm H}$ (400 MHz; CDCl₃) 1.26 (6H, m, 2 × POCH₂CH₃), 1.45 (3H, t, *J* = 6.8 Hz, Ar-OCH₂CH₃), 3.14 (2H, d, *J*_{P,H} = 22 Hz, CH₂P), 4.11 (6H, m, 2 × CH₂OP and Ar-OCH₂CH₃), 7.00 (2H, dd, *J* = 7.8 and 4.6 Hz, ArH), 7.13 (1H, t, *J* = 7.8 Hz, ArH) and 7.77 (1H, d, *J*_{P,C} = 4.4 Hz, 4-H); $\delta_{\rm C}$ (100 MHz; CDCl₃) 14.6 (Ar-OCH₂CH₃), 16.3 (d, *J*_{P,C} = 6.1 Hz, 2 × OCH₂CH₃), 26.6 (d, *J*_{P,C} = 139 Hz, CH₂P), 62.4 (d, *J*_{P,C} = 6.5 Hz, 2 × CH₂OP), 64.9 (Ar-OCH₂CH₃), 114.5, 119.0, 119.9, 120.3, 124.3, 142.0 (d, *J*_{P,C} = 7.8 Hz), 143.1, 146.3 and 147..0 (ArC) and 160.8 (d, *J*_{P,C} = 6.6 Hz, C=O); *m/z* 340 (M⁺, 100%).

Diethyl [(6-chloro-2-oxo-2H-chromen-3-yl)methyl]phosphonate (11c): Yellow solid (0.61 g, 53%), m.p. 72–74°C; (Found M⁺: 330.042081. $C_{14}H_{16}^{35}ClO_5P$ requires M: 330.042389); v_{max} (nujol)/cm⁻¹ 1725 (C=O) and 1260 (P = O); $\delta_{\rm H}$ (400 MHz; CDCl₃) 1.31 (6H, t, J = 7.2 Hz, $2 \times OCH_2CH_3$), 3.18 (2H, d, $J_{\rm PH} = 22$ Hz, CH₂P), 4.13 (4H, m, $2 \times CH_2OP$), 7.27 (1H, s, ArH), 7.44–7.46 (2H, s and overlapping d, ArH) and 7.75 (1H, d, $J_{\rm PC} = 4$ Hz, 4-H); $\delta_{\rm C}$ (100 MHz; CDCl₃) 16.4 (d, $J_{\rm PC} = 6.1$ Hz, $2 \times CH_2CH_3$), 126.8 (d, $J_{\rm PC} = 139$ Hz, CH₂P), 62.5 (d, $J_{\rm PC} = 6.4$ Hz, $2 \times CH_2OP$), 117.9, 120.1 (d, $J_{\rm PC} = 7.9$ Hz) and 151.5 (d, $J_{\rm PC} = 1.9$ Hz) (ArC) and 161.3 (d, $J_{\rm PC} = 6.4$ Hz, C=O); m/z 330 [M⁺ (³⁵Cl), 80%] and 109 (100%).

Diethyl [(6-bromo-2-oxo-2H-chromen-3-yl)methyl]phosphonate (11d): Pale brown oil (0.761 g, 53%); (Found M⁺: 375.849564. $C_{14}H_{16}^{81}BrO_5P$ requires M: 375.850947); v_{max} (nujol)/cm⁻¹ 1725 (C=O) and 1260 (P = O); $\delta_{\rm H}$ (400 MHz; CDCl₃) 1.28 (6H, t, J = 7.2 Hz, 2 × CH₂CH₃), 3.15 (2H, d, J_{P,H} = 22 Hz, CH₂P), 4.10 (4H, q, J = 6.8 Hz, 2x CH₂OP), 7.27–7.45 (3H, series of multiplets, ArH) and 7.74 (1H, d, J_{P,C} = 6.1 Hz, 4-H); m/z 376 [M + 1 (⁸¹Br), 70%] and 109 (100%).

Diethyl (8-ethoxy-3-methyl-2-oxo-2H-chromen-4-yl)phosphonate (12b): Pale Yellow solid (0.186 g, 52%), m.p. 42–45 °C; (Found M⁺: 340.106262. C₁₆H₂₁O₆P requires *M*: 340.107577); v_{max} (nujol)/cm⁻¹ 1709 (C=O) and 1260 (P = O); $\delta_{\rm H}$ (400 MHz; CDCl₃) 1.32 (6H, t, J = 7.2 Hz, 2 × POCH₂CH₃), 1.46 (3H, t, J = 7 Hz, Ar-OCH₂CH₃), 2.60 (3H, d, J_{PH} = 3.2 Hz, 3-CH₃), 4.10–4.27 (6H, m, 2 × CH₂OP and 1 × Ar-OCH₂CH₃), 7.01 (1H, d, J = 8 Hz, ArH), 7.15 (1H, t, J = 8.2 Hz, ArH) and 8.03 (1H, d, J = 8.4 Hz, ArH); $\delta_{\rm C}$ (100 MHz; CDCl₃) 14.7 (Ar-OCH₂CH₃), 16.2 (3-CH₃), 16.3 (d, J_{PC} = 6.2 Hz, 2 × POCH₂CH₃), 62.7 (d, J_{PC} = 5.5 Hz, 2 × CH₂OP), 65.0 (Ar-OCH₂CH₃), 114.0, 118.8 (d, J_{PC} = 11.7 Hz), 119.3 (d, J_{PC} = 1.7 Hz), 123.7, 135.7, 135.8 (d, J_{PC} = 1.6 Hz), 137.5, 142.2 (d, J_{PC} = 1.9 Hz) and 146.3 (d, J_{PC} = 3.7 Hz) (ArC) and 160.6 (d, J_{PC} = 24 Hz, C=O).

Diethyl (6-chloro-3-methyl-2-oxo-2H-chromen-4-yl)phosphonate (12c): Pale yellow solid (0.26 g, 68%), m.p. 76–78 °C; (Found M⁺: 330.042192. C₁₄H₁₆³⁵Cl O₅P requires *M*: 330.042390); v_{max} (nujol)/ cm⁻¹ 1730 (C=O) and 1255 (P = O); $\delta_{\rm H}$ (400 MHz; CDCl₃) 1.34 (6H, t, *J* = 7 Hz, 2 × CH₂CH₃), 2.57 (3H, d, *J*_{P,H} = 3.2 Hz, 3-CH₃), 4.16 and 4.26 (4H, 2 × m, 2 × CH₂OP), 7.19 (1H, d, *J* = 8.8 Hz, ArH), 7.40 (1H, dd, *J* = 8.8 and 2.4 Hz, ArH) and 8.52 (1H, d, *J* = 2.4 Hz, ArH); $\delta_{\rm C}$ (100 MHz; CDCl₃) 16.3 (d, *J*_{P,C} = 6.2 Hz, 2 × OCH₂CH₃), 16.5 ($J_{P,C}$ = 4.1 Hz, 3-CH₃), 63.0 (d, $J_{P,C}$ = 5.6 Hz, 2 × CH₂OP), 117.9 (d, $J_{P,C}$ = 2.4 Hz), 119.1 (d, $J_{P,C}$ = 11 Hz), 127.5, 129.7, 130.7, 134.8, 136.5 (d, $J_{P,C}$ = 9 Hz) and 150.4 (d, $J_{P,C}$ = 13 Hz) (ArC) and 160.4 (d, $J_{P,C}$ = 23 Hz, C=O); *m/z* 330 [M⁺ (³⁵Cl), 100%].

Diethyl (6-bromo-3-methyl-2-oxo-2H-chromen-4-yl)phosphonate (12d): Yellow solid (0.31 g, 65%), m.p. 77–79°C; (Found M⁺: 373.989683. $C_{14}H_{16}^{79}BrO_5P$ requires M: 373.991873); v_{max} (nujol)/ cm⁻¹ 1734 (C=O) and 1240 (P = O); δ_{H} (400 MHz; CDCl₃) 1.36 (6H, t, J = 7.2 Hz, $2 \times CH_2CH_3$), 2.59 (3H, d, $J_{P,H} = 3.2$ Hz, 3-CH₃), 4.18 and 4.27 (4H, $2 \times m$, $2 \times CH_2OP$), 7.16 (1H, d, J = 8.8 Hz, ArH), 7.55 (1H, dd, J = 8.8 and 1.8 Hz, ArH) and 8.69 (1H, d, $J_{P,H} = 2$ Hz, ArH); δ_C (100 MHz; CDCl₃) 16.3 (d, $J_{P,C} = 6.1$ Hz, $2 \times OCH_2CH_3$), 16.5 (d, $J_{P,C} = 4.1$ Hz, 3-CH₃), 63.0 (d, $J_{P,C} = 5.6$ Hz, $2 \times CH_2OP$), 117.2, 118.3 (d, $J_{P,C} = 2.4$ Hz), 119.6, 130.6, 133.5, 134.8, 136.6 (d, $J_{P,C} = 9$ Hz) and 150.8 (d, $J_{P,C} = 13$ Hz) (ArC), and 160.3 (d, $J_{P,C} = 23$ Hz, C=O).

The authors thank the Medical Research Council of South Africa (MRC), the Innovation Fund Programme of the South African Department of Science and Technology, and the National Research Foundation (NRF: GUN 2069255) and Rhodes University for generous bursary and financial support.

Received 19 December 2008; accepted 2 March 2009 Paper 08/0350 doi: 10.3184/030823409X439708 Published online: 26 May 2009

References

- M. Ghate, D. Manohar, V. Kulkarni, R. Shobha and S.Y. Kattimani, *Eur. J. Med. Chem.*, 2003, 38, 297.
- 2 C. Kontogiorgis and D. Hadjipavlou-Litina, J. Enzyme Inhib. Med. Chem., 2003, 18, 63.
- 3 T. Mouri, T. Yano, S. Kochi, T. Ando and M. Hori, J. Pestic. Sci., 2005, 30, 209.
- 4 C. Spino, M. Dodier and S. Sotheeswaran, *Bioorg. Med. Chem.*, 1998, 8, 3475.
- 5 P.J. Tummino, D. Ferguson and D. Hupe, Biochem. Biophys. Res. Commun., 1994, 201, 290. (Chem. Abstr. 1994,121:73068.)
- 6 S. Thaisrivongs, P.K. Tomich, K.D. Watenpaugh, K.H.W. Chong, K. Howe, C. Yang, J. Strohbach, S. Tureer, J. McGrath, M. Bohanon, J. Lynn, A. Mulichak, P. Spinelli, R. Hinshaw, P. Pagano, J. Moon, M. Ruwart, K. Wilkinson, B. Rush, G. Zipp, R. Dalga, F. Schwende, G.P.G. Howard, L. Toth, Z. Zhao, K. Koeplinger, T. Kakuk, S. Cole, R.Zaya, R. Piper and P. Jeffrey, J. Med. Chem., 1994, 37, 3200.
- 7 I.P. Singh, S.B. Bharate and K.K. Bhutani, Curr. Sci., 2005, 89, 2.
- 8 O.A. Lima and J. Polonskwi, *Phytochemistry*, 1973, 12, 913.
- 9 F.M. Dean, Naturally occurring oxygen ring compounds, Butterworths, London, 1963, p. 337.
- 10 M. Maheswar, S. Vidavalur, L. Guri, D. Vasantha, K.R. Yerra and C.V. Rao, J. Mol. Catal., 2006, 255, 49.
- 11 S. Vilar, E. Quezada, L. Santana, E. Uriarte, Y.N. Fraiz, C. Alcaide, E. Cano, and F. Orallo, *Bioorg. Med. Chem. Lett.*, 2006, 16, 257.
- 12 M.M. Heravi, R. Hekmatshoar and M. Emangholizadeh, *Phosphorus, Sulfur Silicon Relat. Elem.*, 2004, **179**, 1893.
- 13 D. Bogdal, J. Chem. Res (S)., 1998, 468.
- 14 O.B. Familoni, P.J. Klaas, K.A. Lobb, V.E. Pakade and P.T. Kaye, <u>Org.</u> *Biomol. Chem.*, 2006, **4**, 3960.
- 15 P.T. Kaye, S. Afr. J. Sci., 2004, 100, 545.
- 16 P.T. Kaye and M.A. Musa, Synth. Commun., 2003, 33(10), 1755
- 17 P.T. Kaye and M.A. Musa, Synthesis, 2002, 2701.
- 18 P.T. Kaye, M.A. Musa and X.W. Nocanda, Synthesis, 2003, 531.
- 19 P.T. Kaye, M.A. Musa, A.T. Nchinda and X.W. Nocanda, Synth. Commun., 2004, 34, 2575.
- 20 J. March, Advanced organic chemistry: reactions, mechanisms and structure, 4th edn, Wiley Interscience, New York, 1992, p. 959.
- 21 P.T. Kaye and M.A. Musa, Synth. Commun., 2004, 34, 3409.
- 22 G.A. Cartwright and H.J. McNab, J. Chem. Res. (S), 1997, 296.